Print This Page

Administrative Supplement for Early Phase Imaging in Therapeutic Clinical Trials - Cancer Imaging Program - Funding Announcement
Release date: April 29, 2009
Receipt date: May 27, 2009
Available funds were: $6,300,000 (total costs)

This initiative was open to those with NCI-funded research projects who applied for an administrative supplement to support early phase advanced imaging in therapeutic clinical trials under approved protocols or protocols to address several scientific areas.

The following clinical trials are being supported with the ARRA funds:

ACRIN ARRA Trials - Supplemental funding to U01 CA080098, P.I. Mitchell Schnall, MD, and U01 CA079778, P.I. Constantine Gatsonis, PhD

ACRIN 6684 - Multicenter, Phase II Assessment of Tumor Hypoxia in Glioblastoma Using 18F-Fluoromisonidazole (FMISO) With PET and MRI ACRIN 6684 Protocol Currently OPEN to accrual

ACRIN 6687 - A Phase 2, Multicenter Evaluation of 18F-Fluoride PET as a Pharmacodynamic Biomarker for Dasatinib, a Src Kinase Inhibitor, in Men With Castration-Resistant Prostate Cancer and Bone Metastases (BMS #180-279) ACRIN 6687 Protocol Currently CLOSED to accrual

ACRIN 6688 - Phase II Study of 3'-Deoxy-3'-18F Fluorothymidine (FLT) in Invasive Breast Cancer ACRIN 6688 Protocol Currently OPEN to accrual

ACRIN 6689 - Randomized, Phase II, Double-Blind, Placebo-Controlled Trial of Conventional Chemoradiation and Adjuvant Temozolomide Plus Cediranib Versus Conventional Chemoradiation and Adjuvant Temozolomide Plus Placebo in Patients With Newly Diagnosed Glioblastoma ACRIN 6689 Protocol Currently CLOSED to accrual

Other ARRA Trial

Two-Compartment Models to Improve Brain Tumor Therapy, Oregon Health and Science University, Edward A. Neuwelt, MD, Supported by supplement to NCI R01 CA137488. Description

ARRA supplement used to perform Phase I/II clinical trials of a macromolecular nanoparticle for dynamic magnetic resonance imaging of vascular effects of therapy in brain and intracerebral tumors. Accrual Complete